<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101235741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32200</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-title-group>
<journal-title>American journal of medical genetics. Part A</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31342617</article-id>
<article-id pub-id-type="pmc">6953247</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.61307</article-id>
<article-id pub-id-type="manuscript">NIHMS1064196</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Objective Measures of Sleep Disturbances in Children with Potocki-Lupski Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kaplan</surname>
<given-names>Kevin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCool</surname>
<given-names>Caroline</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lupski</surname>
<given-names>James R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glaze</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Potocki</surname>
<given-names>Lorraine</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pediatrics, Houston, USA</aff>
<aff id="A2"><label>2</label>Department of Molecular and Human Genetics, Houston, USA</aff>
<aff id="A3"><label>3</label>Department of Human Genome Sequencing Center Baylor College of Medicine Baylor College of Medicine, Houston, USA</aff>
<aff id="A4"><label>4</label>Department of Neurology, Houston, USA</aff>
<aff id="A5"><label>5</label>Department of Children’s Sleep Center, Houston, USA</aff>
<aff id="A6"><label>6</label>Department of Pulmonary, Houston, USA</aff>
<aff id="A7"><label>7</label>Department of Texas Children’s Hospital, Houston, USA</aff>
<author-notes>
<corresp id="CR1">Correspondence to: Lorraine Potocki, M.D., F.A.C.M.G., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine, Texas Children’s Hospital, 6701 Fannin Street, Suite 1560, Houston, TX 77030, Phone: 832-822-4290, Fax: 832-825-1515</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P25">DECLARATION of INTERESTS:</p>
<p id="P26">Kevin Kaplan: no conflicts of interest</p>
<p id="P27">Caroline McCool: No conflicts of interest</p>
<p id="P28">James R. Lupski: Baylor College of Medicine (BCM) and Miraca Holdings have formed a joint venture with shared ownership and governance of the Baylor Genetics (BG), which performs clinical microarray analysis and clinical exome sequencing. J.R.L. serves on the Scientific Advisory Board of the BG. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron pharmaceuticals, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered in the Baylor Genetics Laboratories.</p>
<p id="P29">Daniel Glaze: No conflicts of interest</p>
<p id="P30">Lorraine Potocki: The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered in the Baylor Genetics Laboratories.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>179</volume>
<issue>10</issue>
<fpage>1982</fpage>
<lpage>1986</lpage>
<!--elocation-id from pubmed: 10.1002/ajmg.a.61307-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P1">Potocki-Lupski syndrome (PTLS; MIM 610883) is a neurodevelopmental disorder caused by a micro-duplication, a 3.7 Mb copy number variant (CNV), mapping within chromosome 17p11.2, encompassing the dosage sensitive <italic>RAI1</italic> gene. Whereas <italic>RAI1</italic> triplosensitivity causes PTLS, haploinsufficiency of <italic>RAI1</italic> due to 17p11.2 microdeletion causes the clinically distinct Smith-Magenis Syndrome (SMS; MIM 182290). Most individuals with SMS have an inversion of the melatonin cycle. Subjects with PTLS have mild sleep disturbances such as sleep apnea with no melatonin abnormalities described. Sleep patterns and potential disturbances in subjects with PTLS have not been objectively characterized.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P2">We delineated sleep characteristics in 23 subjects with PTLS who underwent a polysomnogram at Texas Children’s Hospital. 11 of these subjects (58%) completed the Child’s Sleep Habits Questionnaire (CSHQ). Urinary melatonin was measured in one patient and published previously.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">While the circadian rhythm of melatonin in PTLS appears not to be disrupted, we identified significant differences in sleep efficiency, percentage of rapid eye movement (REM) sleep, oxygen nadir, obstructive apnea hypopnea index, and periodic limb movements between pre-pubertal subjects with PTLS and previously published normative data. Data from the CSHQ indicate that 64% (7/11) of parents do not identify a sleep disturbance in their children.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P4">Our data indicate that younger individuals, &lt;10 years, with PTLS have statistically significant abnormalities in five components of sleep despite lack of recognition of substantial sleep disturbances by parents. Our data support the contention that patients with PTLS should undergo clinical evaluations for sleep disordered breathing and periodic limb movement disorder (PLMD), both of which are treatable conditions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Potocki-Lupski Syndrome</kwd>
<kwd>sleep study</kwd>
<kwd>sleep characteristics</kwd>
<kwd>obstructive sleep apnea</kwd>
<kwd>periodic limb movement disorder</kwd>
<kwd>
<italic>RAI1</italic>
</kwd>
<kwd>duplication 17p11.2</kwd>
<kwd>genomic disorder</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>